EGTX (EGTX) News
Follow EGTX (EGTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Egetis Therapeutics AB (publ) (EGTX) Wins FDA OK for EMCITATE in MCT8 Deficiency
Egetis Therapeutics received FDA approval for EMCITATE (tiratricol) to treat peripheral thyrotoxicosis in MCT8 deficiency. U.S. launch is expected in 8—10 weeks; the FDA also granted a Rare Pediatric Disease Priority Rev
REGULATION | Sep 28, 2026, 09:48 PM UTC
L
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) — Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITA
REGULATION | Sep 28, 2026, 09:48 PM UTC
L
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other dr
REGULATION | Sep 28, 2026, 10:45 AM UTC
L
Egetis to present Emcitate clinical data for MCT8 deficiency in September 2026
Egetis Therapeutics AB (EGTX) said clinical data for Emcitate (tiratricol) in the treatment of MCT8 deficiency will be presented at the 47th Annual Meeting of the European…
EQUITY | Sep 04, 2026, 06:00 AM UTC
L
Egetis Therapeutics to participate in September investor conferences
Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) says it will participate in investor conferences in September, including the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026.
EQUITY | Sep 03, 2026, 06:10 AM UTC
L
Tiratricol granted orphan drug designation for MCT8 deficiency in Japan
Tiratricol has been granted orphan drug designation for MCT8 deficiency in Japan.
EQUITY | Aug 31, 2026, 06:00 AM UTC